A New Reactor Concept for Single-Chamber Microbial Fuel Cells and Possible Anti-Fouling Strategies for Long-Term Operation.

Microbial fuel cells are a promising technology for future wastewater treatment, as it allows cleaning and power generation simultaneously. The bottleneck of microbial fuel cells is often its cathodes because they determine the power output. Gas diffusion electrodes might overcome this bottleneck due to their low production costs and high oxygen reduction rates. However, biofilm formation on the gas diffusion electrodes reduces their performance over time. In this work, a new reactor design of the microbial fuel cell using rotating gas diffusion electrodes is presented. The biofilm growth on the electrode during operation was observed and its effect on the performance of the microbial fuel cell was examined. In addition, different antifouling strategies were investigated over a period of 80 days. It was found that already after 7 days of operation a complete biofilm had grown on an untreated gas diffusion electrode. However, this does not seem to affect the performance of the cells in the beginning. Differences in the performance of the reactors with and without an antifouling strategy only become apparent from day 15 onwards. The use of UV radiation and antibacterial membranes leads to the best results with maximum power densities of approx. 200 mW m-2 while the untreated microbial fuel cell only achieves a maximum power density of approx. 20 mW m-2.

Investigation of an electrolysis system with boron-doped diamond anode and gas diffusion cathode to remove water micropollutants.

Using electrolysis systems to degrade organics in wastewater encourages this technique to remove micropollutants (MPs) in different types of water. In this work, a cell consisting of an anode as a boron-doped diamond (BDD) electrode combined with a gas diffusion (GDE) cathode without a separator showed that MPs degradation can be effectively achieved. Investigating different operating parameters, it was stated that applying a low current density (2 mA/cm2) and setting the Reynolds number of the electrolyte flow through the cell at the laminar range raised the treatment time by 3-fold at the same energy demand. This arrangement increased the MPs removal. Some substances like diclofenac were removed up to 84% at a longer treatment time of 180 min coupled with an increase in energy demand. The results at the mentioned parameters indicated an adequate generation rate of radicals needed to remove MPs and the oxidation reactions were promoted. The results show high potential to the investigated electrolysis system in removing MPs in wastewater under considering the need for further reduction of the energy demand.

Cysteine-type cathepsins promote the effector phase of acute cutaneous delayed-type hypersensitivity reactions.

Cysteine-type cathepsins such as cathepsin B are involved in various steps of inflammatory processes such as antigen processing and angiogenesis. Here, we uncovered the role of cysteine-type cathepsins in the effector phase of T cell-driven cutaneous delayed-type hypersensitivity reactions (DTHR) and the implication of this role on therapeutic cathepsin B-specific inhibition. Methods: Wild-type, cathepsin B-deficient (Ctsb-/-) and cathepsin Z-deficient (Ctsz-/-) mice were sensitized with 2,4,6-trinitrochlorobenzene (TNCB) on the abdomen and challenged with TNCB on the right ear to induce acute and chronic cutaneous DTHR. The severity of cutaneous DTHR was assessed by evaluating ear swelling responses and histopathology. We performed fluorescence microscopy on tissue from inflamed ears and lymph nodes of wild-type mice, as well as on biopsies from psoriasis patients, focusing on cathepsin B expression by T cells, B cells, macrophages, dendritic cells and NK cells. Cathepsin activity was determined noninvasively by optical imaging employing protease-activated substrate-like probes. Cathepsin expression and activity were validated ex vivo by covalent active site labeling of proteases and Western blotting. Results: Noninvasive in vivo optical imaging revealed strong cysteine-type cathepsin activity in inflamed ears and draining lymph nodes in acute and chronic cutaneous DTHR. In inflamed ears and draining lymph nodes, cathepsin B was expressed by neutrophils, dendritic cells, macrophages, B, T and natural killer (NK) cells. Similar expression patterns were found in psoriatic plaques of patients. The biochemical methods confirmed active cathepsin B in tissues of mice with cutaneous DTHR. Topically applied cathepsin B inhibitors significantly reduced ear swelling in acute but not chronic DTHR. Compared with wild-type mice, Ctsb-/- mice exhibited an enhanced ear swelling response during acute DTHR despite a lack of cathepsin B expression. Cathepsin Z, a protease closely related to cathepsin B, revealed compensatory expression in inflamed ears of Ctsb-/- mice, while cathepsin B expression was reciprocally elevated in Ctsz-/- mice. Conclusion: Cathepsin B is actively involved in the effector phase of acute cutaneous DTHR. Thus, topically applied cathepsin B inhibitors might effectively limit DTHR such as contact dermatitis or psoriasis. However, the cathepsin B and Z knockout mouse experiments suggested a complementary role for these two cysteine-type proteases.